Struggling with poor bioavailability in your early-phase drug candidates? You're not alone. Low aqueous solubility is a common hurdle, delaying critical First-in-Human (FIH) trials and inflating costs.
But what if you could accelerate development by quickly identifying the optimal drug form and formulation?
This on-demand webinar is your guide to doing just that! Join Lonza's experts, Josh Marsh and Abhijeet Sinha, as they reveal how to confidently:
- Rapidly screen for the best crystalline or amorphous alternatives.
- Predict absorption risks early, saving time and resources.
- Design preclinical and clinical studies with precision for maximum success.
What You'll Gain From This Webinar:
We'll demystify the powerful combination of solid form screening and Physiologically Based Biopharmaceutics Modeling (PBBM) using the cutting-edge GastroPlus® platform. You'll learn:
- How PBBM modeling identifies potential oral absorption risks for early drug candidates.
- The critical role of solid form screening in oral pharmaceutical development.
- How to strategically integrate PBBM with in vitro testing to guide early selection of the ideal drug form and formulation, helping you achieve your preclinical and clinical goals.
We'll walk you through a practical model drug case study, showcasing an optimized pathway to selecting the best lead-enabled form—meaning more efficient progress and a higher likelihood of success for your molecules.
Are These Challenges Familiar to You?
- Selecting the right in vitro dissolution methodology for early-stage API form/formulation.
- Balancing manufacturability, stability, and biorelevant solubility during API screening.
- Using PBBM modeling to predict absorption and inform early-stage form selection.
Don't let poor solubility delay your next breakthrough. Gain the insights you need to accelerate your drug development pipeline.